Stella Aslanyan

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2018 · 374 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial

Stella Aslanyan, Christopher J. Weir, H.‐C. Diener et al. · European Journal of Neurology · 2003 · 336 citations

Medicine, Infectious Diseases, Clinical Epidemiology +16

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

James G. Krueger, Laura K. Ferris, Alan Menter et al. · Journal of Allergy and Clinical Immunology · 2015 · 250 citations

Medicine, Immunology, Pharmacology +15

Effect of Blood Pressure During the Acute Period of Ischemic Stroke on Stroke Outcome

Stella Aslanyan, Franz Fazekas, Christopher J. Weir et al. · Stroke · 2003 · 149 citations

Medicine, Neurology, Pharmacology +17

Associations between meteorological variables and acute stroke hospital admissions in the west of Scotland

Jesse Dawson, Christopher J. Weir, Fiona Wright et al. · Acta Neurologica Scandinavica · 2007 · 111 citations

Public Health, Health Sciences, Meteorology +16